Induction of painless thyroiditis in patients receiving programmed death 1 receptor immunotherapy for metastatic malignancies

Journal of Clinical Endocrinology and Metabolism

Volumn 100, Issue 5, 2015, Pages 1738-1741

  Orlov, Steven ^a   Salari, Farnaz ^a   Kashat, Lawrence ^a   Walfish, Paul G ^a,b  

^a MOUNT SINAI HOSPITAL   (Canada)

^b UNIVERSITY OF TORONTO   (Canada)

Author keywords

[No Author keywords available]

Indexed keywords

ANTINEOPLASTIC AGENT; BETA ADRENERGIC RECEPTOR BLOCKING AGENT; IMMUNOGLOBULIN; LIOTHYRONINE; PROGRAMMED DEATH 1 RECEPTOR MONOCLONAL ANTIBODY; THYROID ANTIBODY; THYROID HORMONE; THYROTROPIN; THYROTROPIN BINDING INHIBITORY IMMUNOGLOBULIN; THYROXINE; UNCLASSIFIED DRUG; MONOCLONAL ANTIBODY; PDCD1 PROTEIN, HUMAN; PROGRAMMED DEATH 1 RECEPTOR;

ADULT; ADVANCED CANCER; AGED; ARTICLE; CANCER IMMUNOTHERAPY; CLINICAL ARTICLE; DRUG EXPOSURE; FEMALE; FREE LIOTHYRONINE INDEX; FREE THYROXINE INDEX; HORMONE SUBSTITUTION; HUMAN; HYPOTHYROIDISM; MALE; METASTASIS; MIDDLE AGED; PAINLESS THYROIDITIS SYNDROME; PRIORITY JOURNAL; THYROIDITIS; THYROTOXICOSIS; TREATMENT DURATION; VERY ELDERLY; ADVERSE EFFECTS; CARCINOMA, NON-SMALL-CELL LUNG; CHEMICALLY INDUCED; IMMUNOLOGY; IMMUNOTHERAPY; LUNG NEOPLASMS; MELANOMA; NEOPLASM METASTASIS; PROCEDURES; SKIN NEOPLASMS;

ADULT; AGED; AGED, 80 AND OVER; ANTIBODIES, MONOCLONAL; CARCINOMA, NON-SMALL-CELL LUNG; FEMALE; HUMANS; IMMUNOTHERAPY; LUNG NEOPLASMS; MALE; MELANOMA; MIDDLE AGED; NEOPLASM METASTASIS; PROGRAMMED CELL DEATH 1 RECEPTOR; SKIN NEOPLASMS; THYROIDITIS; THYROTOXICOSIS;

EID: 84929347192     PISSN: 0021972X     EISSN: 19457197     Source Type: Journal    
DOI: 10.1210/jc.2014-4560     Document Type: Article

References (9)

1. Ginsberg J, Walfish PG. Post-partum transient thyrotoxicosis with painless thyroiditis. Lancet. 1977;1:1125-1128.
2. Papadopoulos KI, Hallengren B. Polyglandular autoimmune syndrome type II in patients with idiopathic Addison's disease. Acta Endocrinologica. 1990;122:472-478.
3. Colao A, Pivonello R, Faggiano A, et al. Increased prevalence of thyroid autoimmunity in patients successfully treated for Cushing's disease. Clinical Endocrinology. 2000;53:13-19.
4. Pearce EN, Farwell AP, Braverman LE. Thyroiditis. New Engl J Med. 2003;348:2646-2655.
5. Ryder M, Callahan M, Postow MA, Wolchok J, Fagin JA. Endocrine-related adverse events following ipilimumab in patients with advanced melanoma: a comprehensive retrospective review from a single institution. Endocrine-related cancer. 2014;21:371-381.
6. Hamid O, Robert C, Daud A, et al. Safety and tumor responses with lambrolizumab (anti-PD-1) in melanoma. New Engl J Med. 2013;369:134-144.
7. Topalian SL, Hodi FS, Brahmer JR, et al. Safety, activity, and immune correlates of anti-PD-1 antibody in cancer. New Engl J Med. 2012;366:2443-2454.
8. Donner H, Braun J, Seidl C, et al. Codon 17 polymorphism of the cytotoxic T lymphocyte antigen 4 gene in Hashimoto's thyroiditis and Addison's disease. J Clin Endocrinol Metab. 1997;82:4130-4132.
9. Donner H, Rau H, Walfish PG, et al. CTLA4 alanine-17 confers genetic susceptibility to Graves' disease and to type 1 diabetes mellitus. J Clin Endocrinol Metab. 1997;82:143-146.